Test Price
2,800 AED✅ Home Collection Available
GNAS Gene Pseudohypoparathyroidism Type 1C Genetic Test in UAE | AED 2,800
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing and orthogonal confirmation.
- Premium Logistics: Hospital‑Grade Home Collection with ISO‑Certified Cold‑Chain and VIP Mobile Phlebotomy (8 AM‑11 PM).
- Clinical Guidance: Complimentary Telephonic Post‑Test Clinical Correlation with a DHA‑licensed Clinical Geneticist.
- Insurance: Direct Billing Verification & Pre‑Approval via WhatsApp: +971 54 548 8731 (Arabic/English).
Test Overview & Methodology
This Next‑Generation Sequencing test targets the full coding region of the GNAS gene to unequivocally confirm Pseudohypoparathyroidism Type 1C (PHP‑1C). The analysis detects single‑nucleotide variants, small insertions/deletions, and is complemented by Sanger confirmation for critical variants. Results enable precise endocrine management and familial cascade screening.
| Parameter | Our Genetic Test | Closest Alternative (Sanger/Biochemical) |
|---|---|---|
| Technology | Targeted NGS with Sanger confirmation | Single‑gene Sanger sequencing or hormone assays |
| Analytical Sensitivity | >99.9% for SNVs/indels | ~95% (may miss mosaic variants) |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks (but often requires reflex testing) |
| Clinical Utility | Definitive molecular diagnosis; enables personalized endocrine management and familial screening | Phenotypic suspicion; may not differentiate PHP subtypes |
| Regulatory Compliance | ISO 9001:2015, DHA‑licensed facility (Lic. 1143) | Variable; often lacks DHA oversight |
Physician Insight & Safety Protocols
“Pseudohypoparathyroidism type 1C is a complex endocrine disorder; genetic confirmation via NGS not only clarifies the diagnosis but guides tailored calcium and vitamin D management, reducing long‑term complications. Always correlate molecular findings with clinical presentation and family history. Treatment decisions must be made by your treating specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Diagnostic Only
Do not discontinue prescribed medication without consulting your doctor. This test is for diagnostic purposes only and must be interpreted in the full clinical context.
Exclusion Criteria
- Active febrile illness or systemic infection
- Severe anaemia (Hb < 7 g/dL) or haemodynamic instability
- Inability to provide a venous blood sample (alternate DNA sources may be discussed)
- Recent whole‑blood transfusion (within 2 weeks) may interfere with germline DNA analysis
ER Red Flags — Seek Immediate Attention
- Seizure or status epilepticus
- Tetany, severe muscle cramping, or carpopedal spasm
- Cardiac arrhythmia or syncope
- Altered consciousness or acute confusion
Patient FAQ & Clinical Guidance
1. What is the purpose of the GNAS Pseudohypoparathyroidism Type 1C NGS test?
This NGS identifies pathogenic variants in the GNAS gene to confirm Pseudohypoparathyroidism Type 1C diagnosis, enabling targeted therapy.
It precisely detects single‑nucleotide variants, small insertions/deletions, and can be complemented by deletion/duplication analysis if needed. The result allows your clinical geneticist to differentiate PHP‑1C from other subtypes and initiate appropriate hormone replacement while planning family‑wide screening.
2. How is the sample collected and what is the turnaround time?
A single blood draw or DNA sample is used; results are available in 3–4 weeks with ISO‑15189 laboratory processing.
We accept whole blood in EDTA vacutainers, extracted DNA, or a drop of blood on an FTA card. Our DHA‑licensed phlebotomists offer home collection across the UAE (8 AM–11 PM) under strict cold‑chain logistics. TAT includes DNA extraction, NGS library preparation, sequencing, bioinformatics analysis, and expert clinical interpretation.
3. Is home sample collection available and covered by insurance in the UAE?
Yes, we offer DHA‑licensed home phlebotomy across all emirates from 8 AM to 11 PM; insurance verification via WhatsApp.
Our mobile phlebotomy service is fully licensed and adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Prior to scheduling, our team validates your insurance coverage and obtains any required pre‑approvals. For minors, written consent from a legal guardian is mandatory in compliance with UAE regulations.
UAE Regulatory & Data Privacy Adherence
This diagnostic test and all associated data handling comply with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE operates under DHA Facility License No. 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | GNAS Gene Pseudohypoparathyroidism Type 1C NGS Test |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Targeted Next-Generation Sequencing with Sanger Confirmation |
| ICD-10-CM Code | E20.1 |
| LOINC Code | 48783-2 |
| DHA Facility License & Laboratory Address | License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians